Rafferty Asset Management, LLC Spero Therapeutics, Inc. Transaction History

Rafferty Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$7.87 - $15.15 $275,119 - $529,613	-34,958 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$13.09 - $18.77 $211,652 - $303,492	16,169 Added 86.06%	34,958 $560,000
Q3 2021 Nov 10, 2021	SELL	$13.03 - $19.51 $66,570 - $99,676	-5,109 Reduced 21.38%	18,789 $346,000
Q2 2021 Aug 10, 2021	SELL	$12.22 - $15.79 $550,694 - $711,576	-45,065 Reduced 65.35%	23,898 $334,000
Q1 2021 May 10, 2021	BUY	$13.23 - $21.48 $912,380 - $1.48 Million	68,963 New	68,963 $1.02 Million

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $40.7M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.